AI assistant
Sending…
Oramed Pharmaceuticals Inc. — Director's Dealing 2016
Sep 8, 2016
6965_dirs_2016-09-08_555cfb30-e984-468f-be7a-8e24189cfd50.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2016-08-30
Reporting Person: Slager David Mark (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1186823 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (Right to Buy) | $3.7656 | 2017-08-28 | Common Stock (112613) | Indirect | |
| Warrants (Right to Buy) | $3.7656 | 2017-11-05 | Common Stock (16892) | Indirect | |
| Warrants (Right to Buy) | $7.2 | 2016-11-29 | Common Stock (137310) | Indirect |
More from Oramed Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 19
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Capital/Financing Update
2026
Feb 20
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 29
Major Shareholding Notification
2026
Jan 29
Director's Dealing
2026
Jan 29